Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Stellis Biopharma gets CDSCO approval to manufacture and export Sputnik Light
Strides Pharma Science Limited's biotech division Stelis Biopharma has commissioned its large-scale, greenfield vaccine manufacturing facility at Bengaluru for producing and supplying 50 million doses of the Russian COVID-19 vaccine Sputnik Light. Strides Pharma Science Ltd - 532531 - Update On Stelis
Stelis Biopharma commissions its greenfield vaccine manufacturing facility at Bengaluru, India, successfully completes the CDSCO inspection for Drug Substance and Drug Product, and receives initial NOC to export 50 million doses of Russian Sputnik Light Vaccine Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our intimation letter dated December 15, 2021 and in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement regarding completion of dispatch of Notice of Postal Ballot dated November 10, 2021, published in Business Standard (English Edition) and in Lokmat (Marathi Edition). A copy of the said advertisement will also be made available on the Company's website at www.strides.com This is for your information and records. Strides Pharma Science Ltd - 532531 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
In line with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we enclose herewith Notice of Postal Ballot dated November 10, 2021 seeking approval of Members of the Company for the resolutions setout in the Notice. Strides Pharma Science Ltd - 532531 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 15, 2021 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Funds Management Pvt Ltd
Earnings Call for Q2FY22 of Strides Pharma Science
Conference Call with Strides Pharma Science Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Pursuant to Regulations 3(2A) and 8(2) of the PIT Regulations, please find enclosed herewith a copy of the revised 'Strides' Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information' (Strides' Fair Disclosure Code), as approved by the Board of Directors of the Company in their meeting held on November 10, 2021. The revised Strides' Fair Disclosure Code is also available on the website of the Company at https://www.strides.com/investor-committeboard.html Request you to kindly take the same on record and oblige.